Trastuzumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Trastuzumab and local guidelines before prescribing.
HER2 monoclonal antibody
Mechanism
HER2 monoclonal antibody.
Uses
HER2-positive breast and gastric cancer.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Cardiomyopathy and heart failure, infusion reactions, diarrhoea, neutropenia.
Interactions
Anthracyclines increase cardiotoxicity.
Contraindications and cautions
Severe dyspnoea at rest, heart failure
Monitoring
LVEF, FBC
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Baseline and 3-monthly echocardiogram; stop if LVEF falls.
More from the textbook: uses, cautions and other points
- Before cardiotoxic cancer treatment (anthracyclines, trastuzumab) | ECG; echo with global longitudinal strain; troponin and NT-proBNP | Repeat imaging during treatment (cardio-oncology)
Cardiology Investigations - Toxic, endocrine and metabolic causes : Excess alcohol consumption; Anthracycline chemotherapy; Trastuzumab-associated cardiac dysfunction; Thyrotoxicosis or severe hypothyroidism; Thiamine deficiency; Severe chronic anaemia.
Cardiology: Heart Failure - Toxic: Alcohol, cocaine, methamphetamine, anabolic steroids, anthracyclines, trastuzumab, radiotherapy.
Cardiology: Cardiomyopathies - Organ toxicities - heart (anthracyclines, trastuzumab, 5-FU), lungs (bleomycin), kidneys (cisplatin), bladder (cyclophosphamide), hearing (cisplatin).
Oncology: Principles - HER2-targeted drugs (breast, gastric): Trastuzumab - cardiotoxicity (echo every 3 months). Trastuzumab deruxtecan - ILD .
Oncology: Principles - Drugs that cause or worsen heart problems - NSAIDs (heart failure, hypertension), steroids, calcium channel blockers (oedema), QT-prolonging drugs, thyroxine, decongestants, anthracyclines and trastuzumab.
Cardiology: History and Examination - HER2-targeted therapy (trastuzumab): Usually reversible LV dysfunction, not dose-related; treatment can often resume after recovery.
Cardiology: Cardiomyopathies - Advanced: Chemotherapy, with nivolumab (selected); trastuzumab for HER2-positive tumours.
Gastroenterology: Oesophagus and Stomach
Where it is discussed in the book
- Cardiology: History and Examination (1 mention)
- Cardiology Investigations (1 mention)
- Cardiology: Heart Failure (1 mention)
- Cardiology: Cardiomyopathies (2 mentions)
- Gastroenterology: Oesophagus and Stomach (1 mention)
- Oncology: Principles (6 mentions)
- Oncology: Emergencies (1 mention)
- Oncology: Breast and Gynae Cancers (9 mentions)
- Surgey: Breast and endocrine surgery (1 mention)
- Clinical pharmacology and prescribing: Prescribing in special groups (1 mention)
- Integrated cardiology chapter (3 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)
- Pathology: Neoplasia - tumour biology, spread, staging and markers (1 mention)